Capricor Therapeutics

Capricor Therapeutics

Yahoo Finance • 13 days ago

Sector Update: Healthcare Stocks Gain Late Afternoon

Healthcare stocks advanced late Monday afternoon, with the NYSE Healthcare Index up 1.5% and the Sta PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premiu... Full story

Yahoo Finance • 26 days ago

Sector Update: Healthcare Stocks Advance Late Afternoon

Healthcare stocks were higher late Tuesday afternoon, with the NYSE Healthcare Index adding 0.6% and PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premiu... Full story

Yahoo Finance • last month

A Rejected Vote Pushes Capricor (CAPR) Toward A Narrower Path

On August 13, Capricor Therapeutics (NASDAQ:CAPR) held its second-quarter earnings call, just over two weeks after an FDA advisory committee voted 3 to 9 against the company's bid to treat cardiomyopathy in Duchenne muscular dystrophy pati... Full story

Yahoo Finance • last month

Capricor slips after report on potential Deramiocel rejection

[An arrow pointing downwards on top of a pile of US dollar bills.] Capricor Therapeutics (CAPR [https://seekingalpha.com/symbol/CAPR]) was a notable decliner in biotech on Thursday after a report from STAT News renewed concerns about a po... Full story

Yahoo Finance • last month

Catalyst Watch: Eyes on Walmart, Alibaba, Reddit, and McDonald's energy drink push

[Stock exchange building columns stock market finance] alexsl Welcome to Seeking Alpha's Catalyst Watch - a breakdown of some of next week's actionable events that stand out. Read more about the events that may impact stock prices next we... Full story

Yahoo Finance • last month

Capricor outlines BLA amendment plan as FDA signals willingness to review, with PDUFA date set for August 22

Earnings Call Insights: Capricor Therapeutics (CAPR) Q2 2026 MANAGEMENT VIEW * Linda Marbán (Co-Founder, President, CEO & Director) said the company’s Deramiocel BLA “remains under review with the FDA with a current PDUFA target action... Full story

Yahoo Finance • 2 months ago

Bronstein, Gewirtz & Grossman LLC Urges Capricor Therapeutics, Inc. Investors to Act: Class Action Filed Alleging Investor Harm

NEW YORK, Aug. 09, 2026 (GLOBE NEWSWIRE) -- Bronstein, Gewirtz & Grossman, LLC, a nationally recognized investor-rights law firm, announces that a class action lawsuit has been filed against Capricor Therapeutics, Inc. (NASDAQ: CAPR) and... Full story

Yahoo Finance • 2 months ago

Capricor Therapeutics, Inc. Notice of September 28, 2026 Application Deadline for Class Action Lawsuit - Contact Reed Kathrein at Hagens Berman Sobol Shapiro LLP Before Application Deadline

SAN FRANCISCO, Aug. 07, 2026 (GLOBE NEWSWIRE) -- Hagens Berman encourages investors in Capricor Therapeutics, Inc. (NASDAQ: CAPR) who suffered substantial losses to submit your losses now. A securities fraud class action lawsuit has bee... Full story

Yahoo Finance • 2 months ago

Catalyst Watch: Inflation reads, AMAT earnings, Google Pixel event, and MLB on Netflix

[Lower Manhattan Cityscape] Art Wager/E+ via Getty Images Welcome to Seeking Alpha's Catalyst Watch - a breakdown of some of next week's actionable events that stand out. Read more about the events that may impact stock prices next week.... Full story

Yahoo Finance • 2 months ago

ROSEN, SKILLED INVESTOR COUNSEL, Encourages Capricor Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - CAPR

NEW YORK, Aug. 07, 2026 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, announces a class action lawsuit on behalf of purchasers of securities of Capricor Therapeutics, Inc. (NASDAQ: CAPR) between December 17... Full story

Yahoo Finance • 2 months ago

CAPR Shareholder Alert: Investors With Losses May Seek to Lead the Class Action in Capricor Therapeutics, Inc. Securities Lawsuit - Contact The Gross Law Firm

NEW YORK, Aug. 07, 2026 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of Capricor Therapeutics, Inc. (NASDAQ: CAPR). Shareholders who purchased shares of CAPR during the class period listed are encou... Full story

Yahoo Finance • 2 months ago

Kaplan Fox Reminds Capricor Therapeutics, Inc. (NASDAQ: CAPR) Investors with Significant Losses to Seek a Leadership Role Before Deadline on September 28, 2026

NEW YORK, Aug. 06, 2026 (GLOBE NEWSWIRE) -- Kaplan Fox & Kilsheimer LLP announces that a class action lawsuit has been filed against Capricor Therapeutics, Inc. (“Capricor” or the “Company”) (NASDAQ: CAPR) on behalf of investors that pur... Full story

Yahoo Finance • 2 months ago

CAPR Alert: Capricor Therapeutics, Inc. (NASDAQ: CAPR) Investors Urged to Contact Hagens Berman; Securities Fraud Class Action Filed, September 28, 2026 Lead Plaintiff Deadline

SAN FRANCISCO, Aug. 05, 2026 (GLOBE NEWSWIRE) -- Hagens Berman encourages investors in Capricor Therapeutics, Inc. (NASDAQ: CAPR) who suffered substantial losses to submit your losses now. A securities fraud class action lawsuit has bee... Full story

Yahoo Finance • 2 months ago

ROSEN, LEADING INVESTOR COUNSEL, Encourages Capricor Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - CAPR

NEW YORK, Aug. 04, 2026 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, announces a class action lawsuit on behalf of purchasers of securities of Capricor Therapeutics, Inc. (NASDAQ: CAPR) between December 17... Full story

Yahoo Finance • 2 months ago

Biotech Stocks Facing FDA Decision In August 2026

(RTTNews) - As we head into August, it's time for our monthly roundup of the upcoming FDA decisions that could move biotech stocks. The August regulatory calendar spans a wide range of indications - from the ultra-rare Fibrodysplasia Ossi... Full story

Yahoo Finance • 2 months ago

Securities Fraud Investigation Into Capricor Therapeutics, Inc. (CAPR) Announced Concerning FDA Review And Advisory Committee Meeting – Shareholders Who Lost Money Urged To Contact Glancy Prongay Wolke & Rotter LLP, a Leading Securities Fraud Law Firm

LOS ANGELES, July 31, 2026 (GLOBE NEWSWIRE) -- Glancy Prongay Wolke & Rotter LLP, a leading national shareholder rights law firm, today announced that it has commenced an investigation on behalf of Capricor Therapeutics, Inc. (“Capricor”... Full story

Yahoo Finance • 2 months ago

CAPR INVESTOR ALERT: Investigation of Capricor Therapeutics, Inc. Announced by Holzer & Holzer, LLC

ATLANTA, July 30, 2026 (GLOBE NEWSWIRE) -- Holzer & Holzer, LLC is investigating whether Capricor Therapeutics, Inc. (“Capricor” or the “Company”) (NASDAQ: CAPR) complied with federal securities laws. On July 27, 2026, STATNews reported... Full story

Yahoo Finance • 2 months ago

Humana upgraded, Las Vegas Sands downgraded: Wall Street's top analyst calls

Humana upgraded, Las Vegas Sands downgraded: Wall Street's top analyst calls The most talked about and market moving research calls around Wall Street are now in one place. Here are today's research calls that investors need to know, as c... Full story

Yahoo Finance • 2 months ago

Capricor Therapeutics Provides Update on FDA Advisory Committee Meeting for Deramiocel

SAN DIEGO, July 30, 2026 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics for rare diseases, today announced that the U.S. Food and Drug Admin... Full story

Yahoo Finance • 2 months ago

CAPR INVESTOR ALERT: Kirby McInerney LLP Announces Investigation Into Potential Securities Fraud

NEW YORK, July 28, 2026 (GLOBE NEWSWIRE) -- The law firm of Kirby McInerney LLP is investigating potential claims against Capricor Therapeutics, Inc. (“Capricor” or the “Company”) (NASDAQ: CAPR). The investigation concerns whether the Co... Full story